Glucotrack is at the forefront of innovation in glucose monitoring technology and is currently advancing toward the commercialization of a revolutionary implantable CBGM system that integrates real-time insights into the fabric of everyday life.
01
Glucotrack is at the forefront of innovation in glucose monitoring technology and is currently advancing toward the commercialization of a revolutionary implantable CBGM system that integrates real-time insights into the fabric of everyday life.
The main challenge in this system is achieving direct blood glucose measurement while maintaining ultra-low power consumption to extend battery life.
02
The main challenge in this system is achieving direct blood glucose measurement while maintaining ultra-low power consumption to extend battery life.
Focus is leading the hardware and firmware design and development for this implantable CBGM system.
03
Focus is leading the hardware and firmware design and development for this implantable CBGM system.
The CBGM system by Glucotrack is a fully implantable device, placed just under the skin.
It features innovative sensor technology that measures glucose levels directly from the bloodstream, offering continuous and precise readings.
The system is designed to work flawlessly for over two years without the need for replacement, representing a significant advancement in CGM technology.
04
The CBGM system by Glucotrack is a fully implantable device, placed just under the skin.
It features innovative sensor technology that measures glucose levels directly from the bloodstream, offering continuous and precise readings.
The system is designed to work flawlessly for over two years without the need for replacement, representing a significant advancement in CGM technology.
Completely subdermal placement removes the discomfort associated with external devices.
Reliable for more than two years, reducing the frequency of replacements.
Ensures real-time, accurate glucose monitoring.
Minimal calibration needed, enhancing convenience.
Over 50% of surveyed CGM users express a preference for this new, non-invasive system.
Completely subdermal placement removes the discomfort associated with external devices.
Reliable for more than two years, reducing the frequency of replacements.
Ensures real-time, accurate glucose monitoring.
Minimal calibration needed, enhancing convenience.
Over 50% of surveyed CGM users express a preference for this new, non-invasive system.
05
Completely subdermal placement removes the discomfort associated with external devices.
Reliable for more than two years, reducing the frequency of replacements.
Ensures real-time, accurate glucose monitoring.
Minimal calibration needed, enhancing convenience.
Over 50% of surveyed CGM users express a preference for this new, non-invasive system.
Though still advancing towards comprehensive human clinical trials, the project has already demonstrated potential to set new standards in diabetes care by improving accuracy, convenience, and user independence.
Preliminary feedback has been overwhelmingly positive, reflecting strong market demand and user approval for the technology.
06
Though still advancing towards comprehensive human clinical trials, the project has already demonstrated potential to set new standards in diabetes care by improving accuracy, convenience, and user independence.
Preliminary feedback has been overwhelmingly positive, reflecting strong market demand and user approval for the technology.
